AR089506A1 - Un conjugado de glp-2 especifico del sitio que emplea un fragmento de inmunoglobulina - Google Patents
Un conjugado de glp-2 especifico del sitio que emplea un fragmento de inmunoglobulinaInfo
- Publication number
- AR089506A1 AR089506A1 ARP120105030A ARP120105030A AR089506A1 AR 089506 A1 AR089506 A1 AR 089506A1 AR P120105030 A ARP120105030 A AR P120105030A AR P120105030 A ARP120105030 A AR P120105030A AR 089506 A1 AR089506 A1 AR 089506A1
- Authority
- AR
- Argentina
- Prior art keywords
- glp
- conjugate
- intestinal
- gastrosis
- treat
- Prior art date
Links
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 title 1
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 title 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 title 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 title 1
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 title 1
- 239000000562 conjugate Substances 0.000 abstract 4
- 238000001727 in vivo Methods 0.000 abstract 2
- 208000028774 intestinal disease Diseases 0.000 abstract 2
- 208000037817 intestinal injury Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000001151 peptidyl group Chemical group 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 101710173664 Glucagon-2 Proteins 0.000 abstract 1
- 102000015626 Glucagon-Like Peptide-2 Receptor Human genes 0.000 abstract 1
- 108010024044 Glucagon-Like Peptide-2 Receptor Proteins 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 abstract 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 239000000863 peptide conjugate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110147684A KR101895047B1 (ko) | 2011-12-30 | 2011-12-30 | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR089506A1 true AR089506A1 (es) | 2014-08-27 |
Family
ID=48698036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120105030A AR089506A1 (es) | 2011-12-30 | 2012-12-27 | Un conjugado de glp-2 especifico del sitio que emplea un fragmento de inmunoglobulina |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9504757B2 (enExample) |
| EP (1) | EP2797621B1 (enExample) |
| JP (1) | JP6131490B2 (enExample) |
| KR (1) | KR101895047B1 (enExample) |
| CN (2) | CN109810198B (enExample) |
| AR (1) | AR089506A1 (enExample) |
| ES (1) | ES2725805T3 (enExample) |
| TW (1) | TWI666219B (enExample) |
| WO (1) | WO2013100704A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
| AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
| US9949927B2 (en) | 2012-04-10 | 2018-04-24 | The Regents Of The University Of California | Bis-polymer lipid-peptide conjugates and nanoparticles thereof |
| EP3046586B1 (en) * | 2013-09-19 | 2021-07-07 | The Regents of The University of California | Methods of treatment using bis-polymer lipid-peptide conjugates and nanoparticles thereof |
| US9994616B2 (en) | 2013-10-15 | 2018-06-12 | The University Of Tokyo | c-Met protein agonist |
| KR102455171B1 (ko) * | 2013-12-18 | 2022-10-14 | 더 스크립스 리서치 인스티튜트 | 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물 |
| MX387560B (es) * | 2014-03-31 | 2025-03-18 | Hanmi Pharmaceutical Co Ltd | Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina. |
| KR101825048B1 (ko) * | 2014-12-31 | 2018-02-05 | 주식회사 제넥신 | GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도 |
| MY206271A (en) | 2016-07-11 | 2024-12-06 | Opko Biologics Ltd | Long-acting coagulation factor vii and methods of producing same |
| CN107987170B (zh) * | 2016-10-27 | 2018-12-18 | 浙江道尔生物科技有限公司 | 一种用于治疗肠道疾病的融合蛋白 |
| AU2018223811B2 (en) | 2017-02-27 | 2021-05-27 | Urigen N.A. | Treatment of lower urinary tract epithelium with glucagon like peptide 2 |
| KR102174436B1 (ko) * | 2017-08-17 | 2020-11-04 | 주식회사 엘지화학 | 불용성 안료 화합물의 정성분석방법 |
| BR112020003736A2 (pt) | 2017-08-22 | 2020-09-08 | Shire-Nps Pharmaceuticals, Inc. | polipeptídeos de fusão de glp-2 e usos para tratar e prevenir condições gastrointestinais |
| EA202090571A1 (ru) * | 2017-09-28 | 2020-07-30 | Ханми Фарм. Ко., Лтд. | Конъюгаты производных glp-2 пролонгированного действия |
| WO2019090209A1 (en) * | 2017-11-06 | 2019-05-09 | Shire-Nps Pharmaceuticals, Inc. | Glp-2 analogs and peptibodies for administration before during, or after surgery |
| JP2022512688A (ja) * | 2018-10-24 | 2022-02-07 | シャイア－エヌピーエス ファーマシューティカルズ インコーポレイテッド | Ｇｌｐ－２融合ポリペプチドならびに消化管の状態の処置および予防のための使用 |
| CA3129576A1 (en) * | 2019-02-11 | 2020-08-20 | Opko Biologics Ltd. | Long-acting glp-2 analogs |
| WO2020198604A1 (en) * | 2019-03-28 | 2020-10-01 | United States Government As Represented By The Department Of Veterans Affairs | Compositions and methods of treating and preventing systemic complications of acute illness |
| MX2022006861A (es) | 2019-12-04 | 2022-07-11 | Scripps Research Inst | Agonistas del receptor glp2 y metodos de uso. |
| JP7846622B2 (ja) * | 2019-12-24 | 2026-04-15 | ハンミ ファーマシューティカル カンパニー リミテッド | Ｇｌｐ－２又はその結合体を含む、代謝性骨疾患の予防又は治療用薬学的組成物 |
| WO2021201654A1 (ko) * | 2020-04-03 | 2021-10-07 | 한미약품 주식회사 | Glp-2 유도체 또는 이의 지속형 결합체를 포함하는 방사선요법, 화학요법, 또는 이들의 조합으로 유발된 점막염의 예방 또는 치료용 약학적 조성물 |
| MX2022014671A (es) * | 2020-05-22 | 2023-02-13 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de conjugado de glp-2 de accion prolongada. |
| CN111560062A (zh) * | 2020-05-26 | 2020-08-21 | 成都圣诺生物制药有限公司 | 一种Elisiglutide的制备方法 |
| WO2022159555A1 (en) * | 2021-01-20 | 2022-07-28 | The Trustees Of Columbia University In The City Of New York | Methods for treating graft-versus-host disease using glp-2 agonists and analogues thereof |
| KR20240032010A (ko) | 2021-06-09 | 2024-03-08 | 더 스크립스 리서치 인스티튜트 | 장기 지속형 이중 gip/glp-1 펩타이드 접합체 및 사용 방법 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| US6924264B1 (en) | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| IL155812A0 (en) | 2000-12-07 | 2003-12-23 | Lilly Co Eli | Glp-1 fusion proteins |
| DK1360202T3 (da) | 2001-02-16 | 2008-09-22 | Conjuchem Biotechnologies Inc | Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser |
| CN1705681A (zh) * | 2002-10-14 | 2005-12-07 | 诺沃挪第克公司 | Glp－2化合物、制剂及其用途 |
| US20070060512A1 (en) | 2003-03-04 | 2007-03-15 | Homayoun Sadeghi | Dipeptidyl-peptidase protected protein |
| ES2383300T3 (es) | 2003-11-13 | 2012-06-20 | Hanmi Holdings Co., Ltd | Fragmento Fc de IgG para un vehículo de fármacos y procedimiento para su preparación |
| HRP20120315T1 (hr) | 2003-11-21 | 2012-05-31 | Nps Pharmaceuticals | Proizvodnja peptida 2 nalik glukagonu i analoga |
| WO2006076471A2 (en) | 2005-01-12 | 2006-07-20 | Nobex Corporation | Bnp conjugates and methods of use |
| UA95235C2 (en) | 2005-05-04 | 2011-07-25 | Зииланд Фарма А/С | Glucagon-like-peptide-2 (glp-2) analogues |
| EA200801174A1 (ru) * | 2005-10-24 | 2009-02-27 | Сентокор, Инк. | Антитела-миметики glp-2, полипептиды, композиции, способы и применения |
| JP2008169195A (ja) * | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| CA2755336C (en) * | 2009-03-20 | 2015-07-14 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| MX2011009803A (es) | 2009-03-20 | 2011-09-30 | Hanmi Holdings Co Ltd | Metodo para preparar un polipeptido conjugado fisiologicamente activo en un sitio especifico. |
| KR101746686B1 (ko) | 2010-10-26 | 2017-06-15 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드―２（ｇｌｐ―２）약물 결합체 |
-
2011
- 2011-12-30 KR KR1020110147684A patent/KR101895047B1/ko active Active
-
2012
- 2012-12-27 AR ARP120105030A patent/AR089506A1/es unknown
- 2012-12-28 WO PCT/KR2012/011748 patent/WO2013100704A1/en not_active Ceased
- 2012-12-28 ES ES12861579T patent/ES2725805T3/es active Active
- 2012-12-28 TW TW101150930A patent/TWI666219B/zh active
- 2012-12-28 EP EP12861579.6A patent/EP2797621B1/en active Active
- 2012-12-28 CN CN201910158317.0A patent/CN109810198B/zh active Active
- 2012-12-28 JP JP2014550024A patent/JP6131490B2/ja active Active
- 2012-12-28 US US14/369,436 patent/US9504757B2/en active Active
- 2012-12-28 CN CN201280071002.9A patent/CN104144697A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2797621A4 (en) | 2015-09-02 |
| KR101895047B1 (ko) | 2018-09-06 |
| CN109810198A (zh) | 2019-05-28 |
| JP2015503554A (ja) | 2015-02-02 |
| WO2013100704A1 (en) | 2013-07-04 |
| CN109810198B (zh) | 2023-06-06 |
| ES2725805T3 (es) | 2019-09-27 |
| US9504757B2 (en) | 2016-11-29 |
| EP2797621B1 (en) | 2019-03-06 |
| TW201333032A (zh) | 2013-08-16 |
| US20140377290A1 (en) | 2014-12-25 |
| TWI666219B (zh) | 2019-07-21 |
| JP6131490B2 (ja) | 2017-05-24 |
| KR20130078634A (ko) | 2013-07-10 |
| CN104144697A (zh) | 2014-11-12 |
| EP2797621A1 (en) | 2014-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR089506A1 (es) | Un conjugado de glp-2 especifico del sitio que emplea un fragmento de inmunoglobulina | |
| AR081042A1 (es) | Peptidos de la superfamilia de glucagon que presentan actividad del receptor acoplado a proteinas g | |
| He et al. | Peptide conjugates with small molecules designed to enhance efficacy and safety | |
| AR071990A1 (es) | Compuesto de insulina lispro pegilada, su uso para la manufactura de un medicamento util para el tratamiento de hipoglicemia o diabetes , composicion farmaceutica que lo comprende y proceso para elaborar dicho compuesto | |
| ECSP19046865A (es) | Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico | |
| CY1119582T1 (el) | Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη | |
| AR067555A1 (es) | Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal | |
| CY1118373T1 (el) | Υψηλης συγκεντρωσης υγρες μορφοποιησεις anti-tnfa αντισωματος | |
| BR112012004696B8 (pt) | composto modulador da atividade de tlr, seu uso, composição farmacêutica, medicamento, kit e combinação | |
| UY33605A (es) | Profarmacos que comprenden un conjugado de conector de exendina | |
| MX2012008603A (es) | Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad. | |
| CY1118891T1 (el) | Συζευγμα ινσουλινης με χρηση θραυσματος ανοσοσφαιρινης | |
| BRPI0815578B8 (pt) | Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer) | |
| EA201590525A1 (ru) | Слитые белки для лечения метаболического синдрома | |
| EA201290722A1 (ru) | Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение | |
| BR112012027759A2 (pt) | Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso | |
| EA201590622A1 (ru) | Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения | |
| BR112015013183A2 (pt) | proteínas de fusão para uso como aperfeiçoadores imunogênicos para indução de respostas de células t específicas para antígenos | |
| CO6491083A2 (es) | Profarmacos que comprenden un conugado de insulina-conector | |
| AR081254A1 (es) | Composicion farmaceutica que comprende ave0010 e insulina glargina | |
| AR100695A1 (es) | Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón | |
| DOP2014000083A (es) | Inmunoenlazadores dirigidos contra el tnf | |
| BRPI0806262A2 (pt) | complexo insulinotrópico usando um fragmento de imunoglobulina | |
| BR112012026213A8 (pt) | Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa | |
| BR112013000255A2 (pt) | ácidos hidróxifenil-hexinoicos substituídos por ariloxialquileno, método para preparação dos mesmos e seu uso dos mesmos como um medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |